The VR23 Antitumor Compound Also Shows Strong Anti-Inflammatory Effects in a Human Rheumatoid Arthritis Cell Model...

Area of Science:

• Pharmacology
• Immunology
• Oncology

Background:

• Proteasome inhibitors are established cancer therapeutics.
• Novel proteasome inhibitor VR23 previously showed antitumor activity with reduced side effects.
• The anti-inflammatory potential of VR23 remains largely unexplored.

Purpose of the Study:

• To investigate the anti-inflammatory activity of VR23.
• To compare VR23's efficacy against other proteasome inhibitors in inflammatory models.
• To explore VR23's potential in treating inflammatory conditions like rheumatoid arthritis and acute lung injury.

Main Methods:

• LPS-induced THP-1 monocyte model to assess cytokine downregulation.
• SW982 synovial cell line and primary human synoviocytes from rheumatoid arthritis patients and healthy donors.
• In vivo studies using a mouse model of LPS-induced acute lung injury.

Main Results:

• VR23 effectively downregulated proinflammatory cytokines (IL-1β, TNF-α, IL-6, IL-8) in monocytes, comparable to dexamethasone.
• Unlike bortezomib and carfilzomib, VR23 showed potent anti-inflammatory activity.
• VR23 downregulated IL-6 and inhibited cell migration in synovial cells, with greater effect in rheumatoid arthritis patient cells.
• VR23 reduced neutrophil migration, TNF-α secretion, and lung inflammation in mice.

Conclusions:

• VR23 exhibits significant anti-inflammatory properties across various models.
• VR23 demonstrates selectivity for rheumatoid arthritis synoviocytes.
• VR23 is effective in both acute and chronic inflammatory conditions.
• VR23 holds potential for cancer control, particularly in managing inflammation-driven tumor development.